INVO Fertility, Inc (NASDAQ:IVF) Short Interest Update

INVO Fertility, Inc (NASDAQ:IVF) saw a significant increase in short interest during the month of June. As of June 30th, there was short interest totaling 760,242 shares, an increase of 461.7% from the June 15th total of 135,347 shares. Currently, 42.8% of the company’s shares are sold short. Based on an average trading volume of 12,658,939 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, INVO Fertility has an average rating of “Moderate Buy” and an average target price of $20.00.

INVO Fertility Price Performance

Shares of IVF stock remained flat at $1.13 during trading hours on Monday. 163,449 shares of the stock traded hands, compared to its average volume of 1,806,388. The company has a quick ratio of 0.87, a current ratio of 0.90 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $2.02 million, a PE ratio of -0.00 and a beta of 2.28. The business’s fifty day moving average is $1.58 and its two-hundred day moving average is $3.32. INVO Fertility has a 52-week low of $1.10 and a 52-week high of $169.60.

INVO Fertility (NASDAQ:IVF) last posted its earnings results on Monday, June 22nd. The company reported ($3.38) earnings per share for the quarter. INVO Fertility had a negative net margin of 183.75% and a negative return on equity of 420.62%. The company had revenue of $2.02 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in INVO Fertility stock. Citadel Advisors LLC acquired a new stake in INVO Fertility, Inc (NASDAQ:IVF) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned 1.19% of INVO Fertility at the end of the most recent quarter. Hedge funds and other institutional investors own 12.02% of the company’s stock.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.